Please assess the completion status of the following clinical trial:

Trial Title: Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were enrolled voluntarily and understood the contents of this clinical trial.~* Male or female Parkinson disease (PD) patients between 50 and 80 years~* Subjects who had not received prokinetics (itopride, mosapride, Corydalis tuber, levosulpiride, domperidone, etc.) at least 2 months prior to baseline visit~* Subjects complained at least one symptom of the following that suggests abnormal bowel functions: anorexia, nausea, abdominal distension, dyspepsia, early satiety, dysphagia, foreign body sensation associated with a meal, symptoms of gastroesophageal reflux, constipation, and defecation problem.~Exclusion Criteria:~* History of a gastrointestinal operation~* Subjects with active gastrointestinal diseases under treatment of gastroenterology within 1 month~* Existence of clinically significant cognitive decline or K-Minimental Status Exam score 20 or less~* Subjects had depression or other psychiatric disorders treated with medications such as antidepressants or antipsychotics; mood tranquilizers, benzodiazepines, and sleep pills were permitted with fixed dose during a period of the clinical trial~* Subjects with severe active comorbidities which could interfere the quality of life of the patient~* Subjects with medical conditions which make difficult to be enrolled to the trial judged by clinicians~* Subjects with hypersensitivity or adverse event related to DA-9701 (Motilitone)~* Prior participation to other clinical trials within 3 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Motilitone arm (Type: EXPERIMENTAL): DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
- Placebo arm (Type: PLACEBO_COMPARATOR): DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).